CClinicalTrials.gg
Status unknownNCT03011411COMEREUpdated Jan 5, 2017

Comparison of Methods to Collect Healthcare Consumption Data of Patients in Clinical Trials With an Economic Evaluation

An observational study in Healthcare Consumption, sponsored by Assistance Publique - Hôpitaux de Paris. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-05.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

The sponsor has not verified this record recently (last verified Dec 2016), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

Pragmatic study comparing historical data from usual collection tools to medical administrative databases (local / national PMSI and CRF / SNIIRAM). There are 3 phases to the data collection:

  1. Collection of hospitalization data from the local PMSI and outpatient data from CRF
  2. Collection of hospitalization data in the national PMSI with a probabilistic matching between local and national PMSI data
  3. Collection of outpatient consumption data from SNIIRAM after matching of data from the national PMSI to the SNIIRAM.
Read the detailed description

In studies assessing therapeutic interventions, an economic evaluation requires the collection of patients' healthcare consumption. Two methods are primarily used in accordance with the recommendations of the National Authority for Health (HAS): case report forms (CRF) for ambulatory care and the local hospital discharge databases (local PMSI) - extracted from participating centers - for hospital care. However, these conventional methods have limits. The first is a declarative and mostly retrospective collection, often misinformed and unverifiable. The second provides high quality data but is far from exhaustive as it only concerns hospitalizations that occurred in the participating center, not those that occurred in other hospitals.

In France, medical administrative databases SNIIRAM (all care reimbursed by the statutory health insurance) and national PMSI (all hospital care) are the "gold standards" for collecting consumer personal care. However, the administrative difficulties associated with accessing these databases prevent researchers from extracting routine care consumption data from these databases for health economic studies, despite the fact that the unreliability of the conventional methods has been objectified in a small number of studies in the literature. These studies are few, have been conducted abroad and seek to compare declarative collections to non-exhaustive medical and administrative data. Moreover, they compare only the number of events collected and not the implication for economic evaluations using those numbers, limiting the applicability of their results to economic assessments.

The main objective of this study is to evaluate the performance of usual collection tools compared to the gold standards (medical and administrative databases) for estimating consumption of inpatient and outpatient care in health economic evaluations. The secondary objectives are to evaluate the impact of the potential underestimation of healthcare consumption on the estimated costs and results of economic assessments by studying the variation of the calculated incremental cost-effectiveness ratio (ICER) and the conclusion of evaluation.

The COMERE population comes from studies in which an economic evaluation for an innovative therapeutic strategy was conducted by the principal investigators's research unity. These studies include at the minimum a collection of hospital care consumption. This data collection must be over by the time for the start of the project. The procedure code and studied pathology alone allow the investigators to identify patients in the national PMSI with a probability greater than 0.9. When adding other information available in the local PMSI, this probability reaches 0.99. The principal investigators of the studies agreed on the use of data from their studies in the context of this research project. Overall, among the studies carried out in our unit, 12 projects funded by the Ministry of Health's program supporting funds for expensive innovative technology (STIC) and 1 national registry matched the study's criteria and were retained. Of these 13 studies: 13 have collected data on hospital care consumption and 8 collected data on ambulatory care consumption. In total, these studies included 87 separate centers and 6,928 patients of which 2,661 have an ambulatory care collection. Their data are completely anonymous.

02

Conditions studied

  • Healthcare Consumption

Keywords

  • methods, qualitative research
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with an initial hospital stay during which the innovative treatment strategy was implemented

Inclusion criteria

Among patients of the source population, patients were included if:

  • Their initial hospital stay (the one during which the innovative treatment strategy was implemented) was found in the local PMSI
  • A probabilistic matching with the national PMSI is possible with a probability equal to 1 (in order to compare the data from the usual collections to the gold standard methods).

Exclusion criteria

Exclusion Criteria:

  • We excluded patients whose initial hospital stay found in the national PMSI was not linkable with other admissions due to a coding error.
05

Study design

Time perspective
Retrospective
Enrollment
1,000 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. the average ratio of the number of hospital stays collected by the usual method / number collected by the gold standard method

    the performance of the hospital care consumption collection by the local PMSI: the average ratio of the number of hospital stays (initial and re-hospitalizations) for a patient during the study follow-up period collected through the local PMSI on the number of hospital stays for this patient over the same period collected with the national PMSI.

    Time frame: 1 day

  2. the average ratio of the number of ambulatory acts performed for a patient collected by the usual method / number collected by the gold standard method.

    the performance of the outpatient care consumption by the CRF: the average ratio of the number of ambulatory acts performed for a patient during the study follow-up period collected by the CRF on the number of acts for the same patient extracted from the SNIIRAM over the same period.

    Time frame: 1 day

Secondary outcomes

  1. Ratio of the cost estimated with the conventional method / estimated with the gold standard

    The secondary endpoints are the following: 1. The ratio of the cost associated with hospital care consumption estimated using data collected by the usual method (local PMSI) on the cost of that consumption estimated using the gold standard method (national PMSI); 2. The ratio of the cost associated with outpatient care consumption estimated using data collected by the usual method (CRF) on the cost of that consumption estimated using data collected with the gold standard method (SNIIRAM);

    Time frame: 1 day

  2. Variation in the ICER with both methods (%)

    The secondary endpoints are the following: The change in the ICER, i.e. the difference between the ICER estimated from the usual method of collection and those estimated using the gold standard method

    Time frame: 1 day

  3. Proportion of studies in which the conclusion would change

    The secondary endpoints are the following: The proportion of studies in which there is a change in the conclusion when the performance of the tools used to collect care consumption is taken into account, in particular in probabilistic sensitivity analyses

    Time frame: 1day

  4. Investigation of the "center" effect and/or "study" effect in the data corresponding to the primary endpoint using intraclass coefficient

    The secondary endpoints are the following: The search for an effect of the hierarchical data structure ("study" effect and "center" effect) on the extent of the variations observed in the primary endpoint.

    Time frame: 1 day

07

Study locations

1 site
  • Hôpital HOTEL DIEU
    Paris, 75004, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03011411
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Jan 5, 2017
Start date
Jan 2008
Primary completion
Jan 2017 (estimated)
Completion
Jun 2017 (estimated)
Last update
Jan 5, 2017

Study contacts

Karine CHEVREUL, Pr MD PhD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion